Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018 09 01; 29(9):1932-1938.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Bendamustine Hydrochloride
Bridged Bicyclo Compounds, Heterocyclic
Chemotherapy-Induced Febrile Neutropenia
Disease Progression
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Humans
Lymphoma, Non-Hodgkin
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local
Rituximab
Salvage Therapy
Sulfonamides

authors with profiles

Mark Kozloff